What was the overall market valuation of the US human vaccines market in 2024?

The overall market valuation of the US human vaccines market was $151.52 Million in 2024. Read More

What is the projected market valuation for the US human vaccines market by 2035?

The projected market valuation for the US human vaccines market is $276.25 Million by 2035. Read More

What is the expected CAGR for the US human vaccines market during the forecast period 2025 - 2035?

The expected CAGR for the US human vaccines market during the forecast period 2025 - 2035 is 5.61%. Read More

Which companies are considered key players in the US human vaccines market?

Key players in the US human vaccines market include Pfizer, Moderna, AstraZeneca, Johnson & Johnson, Sanofi, GlaxoSmithKline, Merck & Co., Novavax, and Bharat Biotech. Read More

What are the market segments based on vaccine type in the US human vaccines market?

The market segments based on vaccine type include Inactivated, Live Attenuated, Subunit, Recombinant, and Toxoid. Read More

What was the valuation range for Inactivated vaccines in 2024?

The valuation range for Inactivated vaccines in 2024 was between $30.0 Million and $55.0 Million. Read More

What is the projected valuation for Preventive Vaccines by 2035?

The projected valuation for Preventive Vaccines is expected to reach between $60.0 Million and $110.0 Million by 2035. Read More

What are the different administration routes for vaccines in the US human vaccines market?

The different administration routes for vaccines include Intramuscular, Subcutaneous, Oral, and Intradermal. Read More

What was the valuation for Influenza Vaccines in 2024?

The valuation for Influenza Vaccines in 2024 was between $41.52 Million and $76.25 Million. Read More

Which target diseases are addressed by vaccines in the US human vaccines market?

Vaccines in the US human vaccines market address target diseases such as Infectious Diseases, Oncological Diseases, and Autoimmune Diseases. Read More

US Human Vaccines Market

US Human Vaccines Market Research Report: Size, Share, Trend Analysis By Vaccine Type (Inactivated, Live Attenuated, Subunit, Recombinant, Toxoid), By Applications (Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, Influenza Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral, Intradermal) and By Target Diseases (Infectious Diseases, Oncological Diseases, Autoimmune Diseases) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

5.61%

2024 Market Size

$ 151.52 Million

2035 Market Size

$ 276.25 Million

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/14106-HCR | Pages: 100 | Author: Satyendra Maurya, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Inactivated
  2. 4.1.2 Live Attenuated
  3. 4.1.3 Subunit
  4. 4.1.4 Recombinant
  5. 4.1.5 Toxoid
2. 4.2 Construction, BY Application (USD Million)
  1. 4.2.1 Preventive Vaccines
  2. 4.2.2 Therapeutic Vaccines
  3. 4.2.3 Travel Vaccines
  4. 4.2.4 Influenza Vaccines
3. 4.3 Construction, BY Administration Route (USD Million)
  1. 4.3.1 Intramuscular
  2. 4.3.2 Subcutaneous
  3. 4.3.3 Oral
  4. 4.3.4 Intradermal
4. 4.4 Construction, BY Target Diseases (USD Million)
  1. 4.4.1 Infectious Diseases
  2. 4.4.2 Oncological Diseases
  3. 4.4.3 Autoimmune Diseases
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Moderna (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 AstraZeneca (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 GlaxoSmithKline (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novavax (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bharat Biotech (IN)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
5. 6.5 US MARKET ANALYSIS BY TARGET DISEASES
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY TARGET DISEASES, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY TARGET DISEASES, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
  4. 7.2.4 BY TARGET DISEASES, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Human Vaccines Market Segmentation

US Human Vaccines Market By Type (USD Million, 2025-2035)

Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid

US Human Vaccines Market By Application (USD Million, 2025-2035)

Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines

US Human Vaccines Market By Administration Route (USD Million, 2025-2035)

Intramuscular
Subcutaneous
Oral
Intradermal

US Human Vaccines Market By Target Diseases (USD Million, 2025-2035)

Infectious Diseases
Oncological Diseases
Autoimmune Diseases

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”